CELU — Celularity Inc.

Is CELU overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Overbought As of August 19, 2026

Celularity Inc. (CELU) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $0.74. The rating moved from Neutral to Overbought on August 19, 2026.

See all overbought Healthcare stocks →

AI analysis

Celularity Inc. (CELU) is a clinical-stage cell therapy company with upside tied to trial readouts, manufacturing scale and partner interest. The equity reflects typical early-stage biotech dynamics: high upside if programs advance or strategic collaborations materialize, but meaningful downside risk from clinical failures, cash runway constraints and dilution. Recent constructive market tone for growth/biologics modestly supports speculative names, but sparse public coverage and thin liquidity make performance sensitive to company-specific announcements. Monitor upcoming clinical milestones, cash position and any partnership or financing activity as primary drivers of near-term valuation changes.

Key factors

  • Early-stage clinical pipeline with potential upside if lead programs show positive data or secure partnerships
  • Limited or negative near-term revenue profile typical of clinical-stage cell therapy companies, implying dependence on financing or collaborations
  • Exposure to growing interest in biologics and cell therapies which could improve capital access and partnering opportunities
  • Manufacturing and scale-up capabilities are critical; success in GMP production would materially de-risk commercialization timelines
  • Macro environment: mild risk-on investor tone and calmer rate expectations may modestly improve appetite for speculative biotech names in the near term
  • Low social and EDGAR signal coverage increases information asymmetry and episodic trading moves around news or financings

Risks

  • High clinical development risk: negative trial results or regulatory setbacks would sharply reduce valuation
  • Cash runway and dilution risk if additional equity raises are required at low prices
  • Manufacturing complexity and supply-chain constraints for cell therapies could delay programs or increase costs
  • Intense competition from better-capitalized cell-therapy and biologics companies and from alternative modality incumbents
  • Low liquidity and thin trading can exaggerate price moves and complicate exits for investors
  • Limited public information and absence of recent filings or social sentiment data increase uncertainty and make near-term outlook binary

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for CELU — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.